ILB-3XX

"ILB-3XX" is a non-specific code name representing a series of investigational drug candidates under development. This series includes distinct drugs such as ILB-3101, ILB-3103, and ILB-31X, each with unique mechanisms of action and therapeutic targets. For instance, ILB-3101 is a fully humanized IgG1 antibody-drug conjugate (ADC) designed to specifically bind to B7-H3, a target widely expressed on solid tumor cells. ILB-3103 acts as an inhibitor of CD276 (B7-H3) and DLL3, primarily investigated for neoplasms like Small Cell Lung Cancer. ILB-31X is an exosome-based therapy that modulates NF-κB activity, with preclinical studies focusing on liver diseases such as fatty liver and acute liver failure. The diverse nature of these candidates means that "ILB-3XX" itself does not refer to a single drug with a singular mechanism or indication.